CClinicalTrials.gg
Sign In
RecruitingNCT07172347Updated Jan 2, 2026

Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo

A Phase 2 interventional study of VC005 tablets and VC005 Tablets Placebo in Non-segmental Vitiligo, sponsored by Jiangsu vcare pharmaceutical technology co., LTD. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-02.

Sponsored by Jiangsu vcare pharmaceutical technology co., LTD · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2025; still recruiting 11 months later.
Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This clinical trial is a multicenter, randomized, double-blind, controlled phase II clinical study

02

Conditions studied

  • Non-segmental Vitiligo
03

In context

Lead sponsor

Jiangsu vcare pharmaceutical technology co., LTD is the lead sponsor of 34 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • The subject understands and voluntarily signs the informed consent form (ICF) and is willing and able to comply with the study protocol.
  • The subject is between 18 and 70 years of age (including borderline values) , regardless of gender.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating women, or subjects with pregnancy or lactation plans during the study period.
  • All hair in the vitiligo area on the face is white.
  • Those who are known or suspected to be allergic to the main ingredients and excipients of VC005 or similar drugs.
  • Subjects who have previously received depigmentation treatment.
  • Subjects who have received experimental drug administration or participated in device clinical trials within the first month or 5 half lives (whichever is longer) prior to randomization.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    VC005 Tablets Low Dose groups

    Drug: VC005 tablets

  • Experimental
    VC005 Tablets High Dose groups

    Drug: VC005 tablets

  • Placebo comparator
    VC005 Tablets Placebo groups

    Drug: VC005 Tablets Placebo

Interventions

  • DrugVC005 tablets

    VC005 groups repeat administration for 52 weeks

  • DrugVC005 Tablets Placebo

    VC005 Placebo groups repeat administration for 52 weeks

06

What researchers measure

Primary outcomes

  1. Percentage change in facial vitiligo area score index (F-VASI) relative to baseline at week 24

    Time frame: Week 24

07

Study locations

1 of 1 sites recruiting
  • The Peking University People's Hospital
    Beijing, Beijng, China
    • Jianzhong Zhang · Contact · rmzjz@126.com · 010-88325471
    • Jianzhong Zhang · Principal investigator
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07172347
Lead sponsor
Jiangsu vcare pharmaceutical technology co., LTD
Responsible party
Sponsor
First posted
Sep 15, 2025
Start date
Oct 31, 2025
Primary completion
Aug 30, 2027 (estimated)
Completion
Aug 30, 2027 (estimated)
Last update
Jan 2, 2026

Study contacts

xiaojuan lai
Contact
lai_xiaojuan@vcarepharmatech.com
15358160458

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Jiangsu vcare pharmaceutical technology co., LTD

Start the discussion